Authors: Webber EM, Lin JS, Evelyn P Whitlock
Title: Oncotype DX tumor gene expression profiling in stage II colon cancer. Application: prognostic, risk prediction.
Journal: PLoS Curr 2:-
Abstract: Overall five-year survival for patients with stage-II colon cancer averages 75% after surgery alone. However, some of these patients have poorer outcomes, similar to patients with stage-III disease. The proposed use of the Oncotype DX assay is to improve risk stratification for recurrence in stage-II colon cancer.
Last Modified: 03 Sep 2013